AIMC Topic: Drug Design

Clear Filters Showing 471 to 480 of 583 articles

De novo synthetic antimicrobial peptide design with a recurrent neural network.

Protein science : a publication of the Protein Society
Antibiotic resistance is recognized as an imminent and growing global health threat. New antimicrobial drugs are urgently needed due to the decreasing effectiveness of conventional small-molecule antibiotics. Antimicrobial peptides (AMPs), a class of...

AI-based IsAb2.0 for antibody design.

Briefings in bioinformatics
Therapeutic antibody design has garnered widespread attention, highlighting its interdisciplinary importance. Advancements in technology emphasize the critical role of designing nanobodies and humanized antibodies in antibody engineering. However, cu...

DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras.

Briefings in bioinformatics
PROteolysis TArgeting Chimeras (PROTACs) has recently emerged as a promising technology. However, the design of rational PROTACs, especially the linker component, remains challenging due to the absence of structure-activity relationships and experime...

A survey of generative AI for de novo drug design: new frontiers in molecule and protein generation.

Briefings in bioinformatics
Artificial intelligence (AI)-driven methods can vastly improve the historically costly drug design process, with various generative models already in widespread use. Generative models for de novo drug design, in particular, focus on the creation of n...

Antibody design using deep learning: from sequence and structure design to affinity maturation.

Briefings in bioinformatics
Deep learning has achieved impressive results in various fields such as computer vision and natural language processing, making it a powerful tool in biology. Its applications now encompass cellular image classification, genomic studies and drug disc...

MvMRL: a multi-view molecular representation learning method for molecular property prediction.

Briefings in bioinformatics
Effective molecular representation learning is very important for Artificial Intelligence-driven Drug Design because it affects the accuracy and efficiency of molecular property prediction and other molecular modeling relevant tasks. However, previou...

Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides.

Briefings in bioinformatics
With their diverse biological activities, peptides are promising candidates for therapeutic applications, showing antimicrobial, antitumour and hormonal signalling capabilities. Despite their advantages, therapeutic peptides face challenges such as s...

NGCN: Drug-target interaction prediction by integrating information and feature learning from heterogeneous network.

Journal of cellular and molecular medicine
Drug-target interaction (DTI) prediction is essential for new drug design and development. Constructing heterogeneous network based on diverse information about drugs, proteins and diseases provides new opportunities for DTI prediction. However, the ...

Piquing artificial intelligence towards drug discovery: Tools, techniques, and applications.

Drug development research
The purpose of this study was to discuss how artificial intelligence (AI) methods have affected the field of drug development. It looks at how AI models and data resources are reshaping the drug development process by offering more affordable and exp...

A new paradigm for applying deep learning to protein-ligand interaction prediction.

Briefings in bioinformatics
Protein-ligand interaction prediction presents a significant challenge in drug design. Numerous machine learning and deep learning (DL) models have been developed to accurately identify docking poses of ligands and active compounds against specific t...